TRA1 mRNA在肝硬化及肝癌组织中表达的研究

目的探讨肝癌(hepatocellular carcinoma,HCC)组织、肝硬化(liver cirrhosis,LC)组织及正常对照组织中肿瘤排斥抗原1(tumor rejection antigen 1,TRA1)mRNA的表达及关系。方法采用逆转录-聚合酶链反应的方法检测34例肝癌患者肝癌组织、癌旁肝硬化组织、非肝癌的肝硬化患者活检组织、肝血管瘤及肝内胆管结石等对照组织中TRA1 mRNA的表达,用捷达801分析软件对结果进行相对定量分析。结果肝癌组织、肝硬化组织、对照组织TRA1 mRNA表达率分别为95.00%、84.21%、50.00%,肝癌组与对照组间表达率的比较,差异有统计学意义(P0.05),肝硬化组织、对照组织表达率之间差异无明显统计学意义(P0.05);肝癌组织、肝硬化组织、对照组织TRA1 mRNA表达量分别为1.67±0.96、1.49±0.53、0.57±0.27;扩增产物表现出表达量的不同,呈现渐变趋势,肝癌组织、肝硬化组织与对照组之间差异有统计学意义(P0.05),肝癌组织与肝硬化组织比较,差异无统计学意义(P0.05)。结论 TRA1参与了肝硬化、肝癌的发生、发展,TRA1可能是肝硬化和肝癌潜在诊断标志物和治疗靶点。

Expression of TRA1 mRNA in hepatocellular carcinoma and liver cirrhosis tissue

Objective To investigate the expression and relationship of TRA1 mRNA among hepatoeellular carcinoma, liver cirrhosis and normal liver tissues. Methods speeimens of hepatocellular carcinoma, liver cirrhosis RT-PCR was used to detect the expression of TRA1 mRNA in 34 and normal liver tissues. Results The expression rates of TRA1 iar hepatocellular carcinoma, liver cirrhosis and normal liver tissues were 95.00% , 84.21% and 50.00% , respectively there were significant differences between hepatocellular carcinoma and normal liver tissues （P 〈 0.05） , but no signifieamt differences between liver cirrhosis and normal liver tissues （P 〉 0.05）. The expression levels of TRA1 mRNA were 1.67±0.96, 1.49±0.53, 0.57±0.27, respectively, which was significantly higher in hepatocellnlar carcinoma and, liver cirrhosis tissues than that in normal liver tissues （P 〈 0.05）. Conclusion TRA1 mRNA is involved in the progression of hepatocellular carcinoma and liver cirrhosis, for therapy. may be a potential biomarker for diagnosis and target for therapy.